At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 162 enrolled
Drug / intervention
Pasireotidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease
In Brief
A Phase 3 clinical trial evaluating Pasireotide for Cushing's Disease. Completed, enrolled 162 participants across 68 sites in 18 countries.
Detailed Summary
This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCushing's Disease
CountriesArgentina, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Poland, Portugal, Spain, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedFeb 2007
Primary CompletionMar 2010
Study CompletionMay 2014
TodayJul 2026
First PostedFeb 12, 2007
Enrollment StartDec 1, 2006
Primary CompletionMar 1, 2010
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.4 years ago
Interventions
Pasireotidedrug